Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy
Status:
Terminated
Trial end date:
2020-12-15
Target enrollment:
Participant gender:
Summary
Evaluating the safety and efficacy of Icotinib administered in 2-month treatments, in
patients with metastatic triple-negative breast cancer that have received at least two prior
treatments.